The marketing authorization application for Xlucane™ in
Xbrane Biopharma AB’s (publ.) (”Xbrane”) interim report for January - September 2021 is now available on the Company’s website, www.xbrane.com.
Financial summary third quarter 2021
- Revenue amounted to SEK 0.0m (0.0).
- Other operating income amounted to SEK 3.5m (4.9).
- EBITDA was
SEK -39.5m (-54.2). - R&D expenses amounted to
SEK -36.5m (-50.5) representing 79 percent (84) of total operating expenses. - The loss for the period was
SEK -45.5m (-57.7). - Earnings per share was
SEK -1.83 (-2.99). - Cash and cash equivalents at the end of the period amounted to SEK 383.4m (123.8).
Financial summary first nine months 2021
- Revenue amounted to SEK 0.0m (0.0).
- Other operating income amounted to SEK 11.1m (14.4).
- EBITDA was
SEK -140.1m (-151.5). - R&D expenses amounted to
SEK -131.7m (-139.7) representing 83 percent (83) of total operating expenses. - The loss for the period was
SEK -155.9m (-163.0). - Earnings per share was
SEK -6.75 (-9.49). - Cash and cash equivalents at the end of the period amounted to SEK 383.4m (123.8).
Numbers in parentheses refer to the corresponding period last year.
Significant events during the third quarter 2021
- In September, the company’s partner
STADA submitted a marketing authorization application for Xlucane™ to theEuropean Medicines Agency (EMA), which was later validated by the agency. - In July, a directed new issue of
SEK 380m before estimated transaction costs was registered, which Xbrane announced and implemented at the end of June. After the issue, the total number of shares and votes in the company amounts to 25,039,906. The company’s registered share capital amounts to aroundSEK 5,613,598 . Xbrane Biopharma was officially certified as aGreat Place to Work® by theGreat Place to Work® Institute.
Significant events after the period
- In October, the company signed a cooperation agreement with
AGC Biologics , with effective dateSeptember 30, 2021 , for upscaling the established manufacturing process of Xcimzane ™ and manufacture the majority of commercial scale batches for the upcoming Phase 1 and Phase 3 studies, and also comparative quality studies (CAA) to demonstrate biosimilarity, required for the marketing authorization application. - In October, Xbrane was granted six new patents by the Patent and Registration Office (PRV).
- In October, the Nomination Committee for the 2022 Annual General Meeting was established and announced.
See below link and call-in details to the presentation below.
Web link: https://edge.media-server.com/mmc/p/xp3g5i77
Confirmation Code: 1692076
Standard international: +44 (0) 2071 928 338
US (Local): +1 646 741 31 67
US (TollFree): +1 877 870 91 35
© Modular Finance, source